Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06807294 · ClinicalTrials.gov registry record · NA

Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)

A NA study of Neuropathy and Peripheral Neuropathy Due to Chemotherapy, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT06807294: Recruiting NA study of Neuropathy and Peripheral Neuropathy Due to Chemotherapy, sponsored by Dana-Farber Cancer Institute.

NCT06807294 is a NA study of Neuropathy and Peripheral Neuropathy Due to Chemotherapy that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants, below the 186-participant average among 22 other Neuropathy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06807294, a NA study of Neuropathy and Peripheral Neuropathy Due to Chemotherapy, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

This research is being done to determine whether a 12-week virtual Tai Chi training program, designed to improve balance and small nerve fiber function, is feasible and acceptable among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).

Primary Outcome

The intervention is considered feasible if 21 participants are enrolled within the first 6 months of the study period.

Interventions

  • BEHAVIORAL Tai Chi Program

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2026-01-16
Est. Completion 2026-10-31
Phase NA
Dana-Farber Cancer Institute

781 total trials

What NCT06807294 shows while recruiting

NCT06807294 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 186-participant average among 22 other Neuropathy trials with a reported enrollment target (89% lower).

The record links to 4 conditions, with Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Tai Chi Program is the first listed.

NCT06807294 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06807294 about?

NCT06807294 is a clinical study titled "Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)". This research is being done to determine whether a 12-week virtual Tai Chi training program, designed to improve balance and small nerve fiber function, is feasible and acceptable among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).

What is the current status of trial NCT06807294?

This trial is currently recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2026-01-16. Estimated completion is 2026-10-31.

What conditions does trial NCT06807294 study?

This clinical trial studies the following conditions: Neuropathy, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathies, Chemotherapy Induced Peripheral Neuropathy (CIPN).

What interventions are being tested in trial NCT06807294?

The interventions under investigation include: Tai Chi Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06807294?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06807294 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06807294's enrollment target sits among peer trials

21 21st of 22 higher than 2 of 22 other Neuropathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06807294, the US trial registry maintained by the National Library of Medicine. NCT06807294 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.